Haptens (i.e. biomolecules which molecular weight is lower than 10 kDa) 13 determination by inductively coupled plasma mass spectrometry (ICP-MS) is 14 usually performed by means of competitive immunoassays. In these 15 immunoassays, analyte quantification is indirectly carried out using two different 16 tracer species (i.e. antibodies or antigen-protein conjugates). However, the 17 benefits (and drawbacks) derived from using a given tracer species have not 18 been systematically investigated so far. The goal of this work is to evaluate the 19 influence of the tracer species employed in competitive immunoassays on the 20 analytical figures of merit for aflatoxin M 1 (AFM 1 ) determination in milk samples. 21
antigen-protein conjugate as the tracer one (as in the CIA and CBIA strategies). 27
The limit of detection afforded by ABIA strategy (i.e. 0.1 ng kg -1 ) for AFM 1 28 determination was 1000-fold and 50-fold lower regarding the CIA and CBIA 29 strategies, respectively. In the case of the ABIA approach, the characteristics of 30 the metal nanoparticle label employed to detect the tracer species is critical on 31 the analytical figures of merit. However, when the hapten-protein conjugates are 32 used as tracer species, immunocomplex formation is severely hampered by 33 steric effects caused by the protein moiety and, consequently, the 34 characteristics of the metal nanoparticle label is not critical in the immunoassay 35 performance. The different immunoassay strategies were successfully validated 36 for AFM 1 determination in milk samples using a certified reference material of 37 whole milk powder (ERM-BD283) according to European Conformity guidelines 38 for analytical methods of food contaminants and mycotoxins. Compared to 39 ELISA, the immunoassay developed for AFM 1 determination in milk samples 40 improve limits of detection up to 10-fold. 41 previously captured on the solid support (i.e. sandwich assay). The latter 77 antibody is previously labelled with a heteroatom detectable by ICP-MS (e.g. 78 lanthanides, Quantum-Dots, metal nanoparticles, etc.) thus enabling analyte 79 detection. The signal registered by the ICP-MS is proportional to the analyte 80 concentration in the sample. Dealing with haptens (i.e. biomolecules which a 81 molecular weight is lower than 10 kDa), sandwich-based immunoassays cannot 82 be employed since the limited surface area of this type of molecules does not 83 allow to simultaneously accommodate two antibodies [16] . Therefore, haptens 84 are usually determined by means of competitive-immunoassays. In this type of 85 immunoassay, unlike non-competitive immunoassays, the quantity used of the 86 tracer species is limited. Two different strategies have been mainly described in 87 the literature for competitive immunoassays with ICP-MS detection so far. In the 88 first approach, the sample is spiked with a limited amount of the antibody and 89 the mixture is incubated on a solid phase coated with an antigen-protein 90 conjugate. Next, a competitive reaction, for the limited number of the binding 91 sites of the antibody, is established between the antigen bound to the solid 92 phase and that present in the solution. The amount of the antibody retained on 93 the solid support is inversely proportional to the antigen present in solution. To 94 determine the antibody retained on the solid support, it should be previously 95 labelled with a heteroatom [11] . Nevertheless, to preserve antibody activity and 96 specificity against the antigen, it could be also detected after an immunoassay 97 procedure using a metal-labelled secondary antibody with or without biotin-98 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 [14, 15] . In this case, the antigen-protein conjugate is initially labelled with a 101 heteroatom. Next, the sample is spiked with a limited amount of the labelled 102 antigen-protein conjugate and the mixture is incubated on a solid phase coated 103 with the antibody. Again, the amount of tracer species (antigen-protein 104 conjugate) retained on the solid support is inversely proportional to the antigen 105 present in the liquid phase. Up The goal of this work is to perform a systematic comparison of different 116 competitive immunoassays for hapten determination by means of ICP-MS 117 detection. To this end, different competitive immunoassays based on the use of 118 either antibody or antigen-protein conjugate as tracer species were 119 investigated. Nanoparticles covering different elements (Ag/Au) and sizes 120 
Introduction

Reagents and materials 128
Primary rabbit polyclonal anti-aflatoxin M 1 (AFM 1 ) antibody (pAb) (purified 129
IgG fraction 1 mg mL -1 ) was obtained from Agrisera (Vännas, Sweden) whereas 130 secondary anti-rabbit IgG (whole molecule) -Biotin antibody produced in goat 131 (secondary Ab) (1 mg mL -1 ) was from Sigma-Aldrich (Steinheim, Germany). 132
According to the supplier, pAb is highly specific for AFM 1 determination with low 133 cross-reactivity against other aflatoxins (aflatoxin B 1 2%; aflatoxin B 2 , 0.4%; 134 aflatoxin G 1 0.4% and aflatoxin G 2 0.1%). 
Buffers and solutions 164
The standard stock solution of AFM 1 (5 µg mL -1 ) was prepared by dissolving 165 the standard AFM 1 in pure acetonitrile. Working solutions for standards or 166 spiked milk samples were prepared by further dissolution of stock solution in 167 incubation media or in milk, respectively. Aflatoxin M 1 -BSA conjugate was 168 dissolved in phosphate buffer saline solution for a final concentration of 500 µg 169 mL -1 . Both solutions were kept at -20°C in aliquots out of direct light and 170 working solutions were prepared prior to each analysis. Primary rabbit 171 polyclonal antibody was stored at 4°C after reconstitution in 500 µL ultrapure 172
The following solutions were employed in the different immunoassays 174 tested: (i) phosphate-buffered saline (PBS; 10 mM NaH 2 PO 4 , 2 mM Na 2 HPO 4 , 175 154 mM NaCl, pH 7.6); (ii) carbonate buffer solution (15mM Na 2 CO 3 and 35 mM 176 NaHCO 3 , pH 9.6); (iii) as plate blocking medium: 1% w V -1 BSA in PBS; (iv) as 177 incubation medium: 1% w V -1 BSA and 0.05% V V -1 Tween 20 in PBS; (v) as 178 washing medium: 0.05% V V -1 Tween 20 in PBS; (vi) as Au-nanoparticles 179 digestion medium: 4% V V -1 nitric acid and 12% V V -1 hydrochloric acid; and (vii) 180
as Ag-nanoparticles digestion medium: 2 % V V -1 nitric acid. It is important to 181 remark that the use of BSA in the incubation media is critical to ensure 182 immunoassay reproducibility. Considering that the pAb was produced in rabbits 183 by immunization with BSA haptenized with AFM 1 , the pAb could react either 184 with the AFM 1 or BSA present in the AFM 1 -BSA conjugate. Moreover, bovine 185 milk contains a significant amount of this protein (≈1.2% w V -1 ). Therefore, we 186 employed BSA as an additive in all incubation media and could consequently 187 minimize nonspecific binding. 188 189
Immunoassay procedures 190
In the present work, three different competitive immunoassay strategies 191 based on the use of either antibody or antigen-protein conjugate as tracer 192 species were evaluated for AFM 1 determination by means of inductively 193 coupled plasma mass spectrometry (ICP-MS) detection ( Fig. 1) . Next, and given the bivalent nature of the antibodies, the AFM 1 -pAb and the 233 biotinylated AFM 1 -BSA-pAb complexes generated were retained by the AFM 1 -234 BSA conjugates coating the solid phase. Streptavidin-metal nanoparticle 235 conjugates were used again to detect the biotinylated AFM 1 -BSA-pAb 236 complexes retained on the solid phase. This immunoassay strategy has never 237 been employed for hapten analysis with to the best of author's knowledge. 238
The CBIA immunoassay procedure is carried out as follows. Plates were 239 coated at room temperature with 100 µL/well of the appropriate AFM 1 -BSA 240 conjugate concentration in 0.05 M carbonate-bicarbonate buffer (pH 9.6). After 241 incubation for 1 h, plates were washed three times and then blocked (200 242 µL/well) for 1 h at room temperature. Then, after a washing step, samples or 243 AFM 1 standards, pAb and biotinylated AFM 1 -BSA conjugate solutions were 244 mixed ( Fig. 1, step 3 .1) and transferred to the solid phase (100µL/well) ( Fig. 1,  245 step 3.2). Next, the mixture was incubated for 1 h at room temperature. After a 246
conjugates solution was added and incubated for 1 h at room temperature ( Fig.  248 1, step 3.4). 249
250
The biotinylated AFM 1 -BSA conjugate required for the CIA and CBIA 251 procedures was obtained using a commercial biotin labelling kit. Briefly, 2.3 mg 252 of succinimidyl-6-(biotinamido)hexanoate was dissolved in 500 µL of 253 dimetylformamide and then added to a 200 µL AFM 1 -BSA conjugate solution. 254
The reaction was carried out on ice for 2 hours in the dark and the excess of rate was set at 0.6 mL min -1 for high throughput analysis. 286
Two different carrier solutions were selected depending on the chemical 287 nature of the nanoparticle. A mixture of 1% V V -1 nitric acid and 1% w V -1 288 thiourea solution was employed for 107 Ag + measurements whereas a 1% V V -1 289 hydrochloric acid and 1% w V -1 thiourea mixture was employed as carrier for 290 197 Au + determination. Operating in this way, no significant memory effects were 291 registered in ICP-MS [18] . Microsoft Excel software was employed to integrate 292 peak signals manually, given the peak-shape signal obtained with the flow 293 injection analysis device employed. numbers and ionization potentials [19] . The ERM-BD283 milk powder (10.0 g) was suspended in 100 mL of warm 318 ultrapure water (being AFM 1 final concentration of 11.1 ± 1.8 ng L -1 ) , and then 319 processed as for milk samples. 320
otherwise, accuracy and precision would be severely compromised. To this end, 323 two different approaches were employed through this work depending on the 324 immunoassay employed. In the case of ABIA strategy, samples were 325 pretreated, as described in our previous work [13], using the procedure 326 described by Huang et al. [20] based on an extraction pretreatment into a polar 327 solvent. On the other hand, in the case of using the antigen-protein conjugate 328 as tracer species, milk samples were pretreated using immunocolumns 329 following the procedure suggested by the manufacturer with some minor 330 modifications. Briefly, a 100 mL volume of undiluted milk was centrifuged at 331 1614 × g for 15 min to separate the fat and thin upper fat layer was discarded. 332
Fifty mL of the centrifuged milk were passed through the immunoaffinity column 333 at 1-2 drops/second by gravity. Then, the column was washed with 10 mL of 334 water at a rate of 1-2 drops/second until air came through the column. Aflatoxin First, the optimum AFM 1 -BSA conjugate concentration and the optimum 375 pAb concentration were investigated. The AFM 1 -BSA conjugate concentration 376 was modified between 0.07 and 10 µg mL -1 whereas the pAb concentration 377 ranged from 0.015 to 2 µg mL -1 . The streptavidin-metal nanoparticle conjugates 378 concentration was kept at 0.08 µg mL -1 for these experiments. The optimum 379 AFM 1 -BSA conjugate concentration was similar for all streptavidin-metal 380 nanoparticle conjugates (i.e. 0.35 µg mL -1 ), but significant differences were 381 noted on the optimum pAb concentration. The optimum pAb concentration using 382 both 80 nm Ag and Au nanoparticles was 0.015 µg mL -1 whereas it was 0.25 µg 383 mL -1 for 40 nm Ag nanoparticles (Table S1 ). Interestingly, the optimum pAb 384 concentration using 40 nm Ag nanoparticles was similar to that previously found 385 for 40 nm Au counterparts [13] . From these findings, it could be derived that for 386 this assay, the analytical figures of merit afforded are expected to be strongly 387 dependent on the size of the nanoparticle employed. Figure 2 Similar findings were observed for Ag nanoparticles but the LoD obtained were 400 significantly higher than those obtained using Au nanoparticles. Thus, the LoD 401 for 80 nm and 40 nm Ag nanoparticles were 2 and 12 ng kg -1 , respectively. The 402 origin of these differences is not totally clear; since for a given nanoparticle size, 403 optimum immunoassay conditions does not depend on the chemical nature of 404 the metal nanoparticle. Nevertheless, it should be considered that 197 Au + 405 sensitivity in ICP-MS is higher than that of 107 Ag + , mainly due to the isotopic 406 abundance of each nuclide ( 107 Ag + 51.8%; 197 Au + 100%). Therefore, and 407 considering that a competitive-based immunoassay is operated, Au 408 nanoparticles of the same size allow a better discrimination of low AFM1 levels 409 with regard to Ag counterparts (See Fig S1) . On the other hand, it is also worth 410 to stress that the use of Ag nanoparticles was tricky due to a build-up of Ag 411 metallic deposits into the injector tube that could even lead to full blockage. This 412 phenomenon was also noticed for Au nanoparticles but the metallic deposit 413
formation was significantly lower. The influence of the streptavidin-metal 414 nanoparticle conjugates concentration on the analytical figures of merit was also 415 investigated. This parameter was modified between 0.02 and 0.32 µg mL -1 . It 416 was observed that signals registered by the mass spectrometer increased with 417 the streptavidin-metal nanoparticle conjugates concentration, but no changes 418 were found in the optimum pAb and AFM 1 -BSA conjugate concentration and, 419 therefore, in the LoD obtained for the nanoparticles tested (Table S2 ). For this 420 reason, regardless of the streptavidin-metal nanoparticle conjugate used, a M A N U S C R I P T
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18 between analytical performance and cost. These results were similar to those 423 previously reported for 40 nm Au nanoparticles [13] ; thus, pointing out that this 424 parameter was not critical for the immunoassay performance. 425 Table 2 summarizes the optimum immunoassay conditions for each 426 streptavidin-metal nanoparticle conjugate investigated. This table also includes 427 the concentration of AFM 1 giving rise to a 50% inhibition (IC 50 ), LoD and the 428 lower and the upper quantification limits (lLoQ and uLoQ, respectively). The 429 lLoQ was defined as the lowest concentration that signal response has 430 repeatability lower than 20% [24] . Similarly, the uLoQ was defined as the 431 highest concentration that signal response has repeatability lower than 20% 432 First, the pAb concentration and the biotinylated AFM 1 -BSA conjugate 447 nominal concentration were optimized. The pAb concentration ranged from 0.6 448 to 10 µg mL -1 whereas the biotinylated AFM 1 -BSA conjugate nominal 449 concentration was tested between 0.02 and 1.5 µg mL -1 . For these experiments, 450 the streptavidin-metal nanoparticle conjugates concentration was kept constant 451 at 0.08 µg mL -1 . Experimental results showed that the optimum conditions were 452 2.5 µg mL -1 for pAb and 0.05 µg mL -1 for biotinylated AFM 1 -BSA conjugate 453 (Table S3 ). Next, the influence of the streptavidin-metal nanoparticle conjugates 454 concentration on the analytical figures of merit was investigated. This parameter 455 was modified between 0.02 and 0.32 µg mL -1 . As it was shown for ABIA 456 strategy, 107 Ag + or 197 Au + signals increased with the streptavidin-metal 457 nanoparticles conjugate concentration but no significant changes were found in 458 the optimum pAb and biotinylated AFM 1 -BSA conjugate nominal concentration 459 previously obtained as well as on the LoD (Table S4 ). Therefore, the 460 streptavidin-metal nanoparticles conjugate concentration was kept at 0.08 µg 461 mL -1 to minimize operative cost. Under these experimental conditions, for each 462 of the streptavidin-metal nanoparticle conjugates (Figure 4 ), a calibration curve 463 was prepared. A LoD of 100 ng kg -1 was always obtained, regardless of the size 464 and the chemical nature of the nanoparticle employed (Table 2) . Though this 465 value was similar to that previously reported for progesterone analysis [15] 466 using an antigen-protein conjugate as tracer species, it was significantly higher 467 (Table S5) . From these findings, the detection capability is thought to be derived 474 from the immunoassay procedure itself. It should be considered that, given the 475 size of the BSA moieties (66 kDa), high steric effects are expected when 476 biotinylated AFM 1 -BSA conjugates are captured by the pAbs coating the 477 microtiter plate. Obviously, steric effects are more significant as the AFM 1 478 content in the sample decreases since more biotinylated AFM 1 -BSA conjugates 479 are captured on the solid phase. To address this issue, some modifications 480 were implemented in this type of immunoassay to favor the immunocomplex 481 formation. Thus, the immunocomplexes were generated in a homogeneous 482 phase rather than in a heterogeneous phase; minimizing steric effects and, 483
given that the antibodies are bivalent molecules, the immunocomplexes formed 484 were retained in a microtiter plate coated with the antigen-protein conjugate. To 485 our best knowledge, this is the first time that this strategy is employed for 486 hapten analysis. From now on, as mentioned above, this immunoassay will be 487 called capture bridge inhibition assay (CBIA). 488
The optimization of CBIA was carried out likewise the CIA procedure but 489
including the concentration of the AFM 1 -BSA conjugates coating the microtiter 490 plate. After some preliminary test, this concentration was observed to be not 491 critical for the immunoassay. This reagent had just to be in excess to maximize 492 the immunocomplex capture and, hence, this parameter was kept at 1 µg mL -1 . 493
Next, a checkerboard titration procedure was employed to optimize the was tested from 0.01 to 0.64 µg mL -1 . During this optimization, a streptavidin-498 metal nanoparticle conjugates concentration of 0.08 µg mL -1 was employed. A 499 satisfying compromise between an optimum analytical sensitivity with a 500 consistent readout was obtained using 2 µg mL -1 pAb and 0.04 µg mL -1 501 biotinylated AFM 1 -BSA conjugate for all streptavidin-metal nanoparticles 502 conjugate tested (Table S6 ). The influence of the streptavidin-metal 503 nanoparticle conjugates concentration, as it was previously observed for CIA 504 strategy, did not have a significant effect on the LoD (Table S7 ). Therefore, the 505 streptavidin-metal nanoparticles conjugate concentration was again kept at 0.08 506 µg mL -1 as compromise between analytical performance and cost. Under these 507 conditions, as it was previously noticed for the CIA procedure, LoD for AFM 1 508 determination was independent on the streptavidin-metal nanoparticles 509 conjugate employed, both chemical nature and size ( Figure 5 ). Nevertheless, 510 steric effects were less significant in the new approach since LoD for CBIA 511 strategy (5 ng kg -1 ) was improved 20-fold regarding CIA strategy (Table 2) . In 512 general, no significant differences were observed on the dynamic range for both 513 CIA and CBIA strategies. 514 515
Comparison of the competitive immunoassays studied for AFM 1 analysis 516
From data gathered in the previous section, the use of the pAb as tracer 517 species (as in the case of the ABIA procedure) seems to be more 518 advantageous than the use of the antigen-protein conjugate as the tracer one 519 (as in the case of CIA/CBIA strategies) for AFM 1 analysis at ultratrace levels.
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22 not impeded by steric effects since, given the volume occupied by the BSA 522 residues on the solid phase, pAbs have enough space to form the 523 immunocomplexes without interacting with their neighbours (Figure 1 ). In this 524 case, the use of big diameter nanoparticles is indeed advantageous to detect 525 low amounts of pAb retained on the solid phase. In fact, using streptavidin-80 526 nm Au nanoparticle conjugates, the LoD for ABIA strategy was 1000-fold and 527 50-fold lower regarding CIA and CBIA strategies, respectively. The LoD 528 obtained with the ABIA method (0.1 ng kg -1 ) was low enough to quantify AFM 1 529 according to the different international policies. The European Community 530 legislation limits AFM 1 levels in milk and infant formula at 50 and 25 ng kg -1 , 531 respectively; [25, 26] whereas Food and Drug Administration from USA does 532 allow AFM 1 levels up to 500 ng kg -1 [27] . As regards CIA and CBIA strategies, 533 steric effects control the immunocomplex formation and, consequently, no direct 534 advantages are derived from using metal nanoparticles of different chemical 535 nature and size. Nevertheless, LoD afforded by CBIA (namely, 5 ng kg -1 ) was 536 still low enough to control AFM 1 levels according to international policies. 537
Regarding the CIA method (with a LoD of 100 ng kg -1 ), it can only be used to 538 control the AFM 1 levels according to USA guidelines but no according to EU 539 ones. On the other hand, an additional benefit derived from ABIA strategy was 540 the reduction of the amount of pAb required in the immunoassay procedure by 541 two orders of magnitude regarding CIA and CBIA strategies, thus decreasing 542 immunoassay costs. Nevertheless, this cost reduction is counterbalanced by 543 the need of a secondary Ab. The main benefit of using CIA and CBIA methods 544 is the higher sample throughput since the whole immunoassay procedure takes 
Method validation for AFM 1 analysis in milk 549
Both ABIA and CBIA methods were validated for AFM 1 analysis in milk 550 samples according to European Conformity guidelines for analytical methods of 551 food contaminants and mycotoxins [25, 26] . Capture inhibition assay strategy 552 was discarded due to its limited capability to control AFM 1 levels according to 553 EU policy. Streptavidin-80 nm Au nanoparticle conjugates were used for AFM 1 554 determination by means of ABIA method due to its higher detection capabilities. 555
As regards CBIA strategy, though the metal nanoparticle characteristics were 556 not critical, 80 nm Au nanoparticles were employed for the sake of comparison. 557
To evaluate the accuracy and precision of the methods, they were applied to 558 the determination of AFM 1 in the ERM-BD283 milk powder reference material 559 and recovery studies were carried out by spiking milk samples with AFM 1 560 standard at concentration levels over (80 ng kg -1 ) and below (30 ng kg -1 ) the 561 limits established by the EU policy. 562
Initially, irrespective of the immunoassay procedure employed, all milk 563 samples were analyzed after an extraction pretreatment with acetonitrile to 564 mitigate the effects of matrix components (i.e., proteins, fats, etc.). This 565 procedure was selected due to its simplicity and the good results afforded in our 566 previous work using streptavidin-40 nm Au nanoparticle conjugates in the ABIA 567 strategy [13]. However, AFM 1 recoveries were systematically higher than 100% 568 for both ABIA and CBIA procedures using streptavidin-80 nm Au nanoparticle 569 conjugates (Table S8) . From these results, it can be derived that both types of M A N U S C R I P T
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24 immunoassays suffer from strong matrix effects caused by the milk components 571 that are still present in the acetonitrile extract phase. In the case of ABIA 572 strategy, these results could be attributed to the lower pAb concentration 573 employed since it makes the immunoassay more sensitive to lower AFM 1 574 concentrations but also to matrix components. Taking into account the LoD 575 afforded by the ABIA method, milk samples could be diluted to mitigate matrix 576 effects without compromising analyte quantification [12] . To this end, before the 577 extraction pretreatment, milk samples were diluted with the appropriate volume 578 of ultrapure water. It was observed that matrix effects disappeared after a 4-fold 579 milk dilution (Table S8) . Table 3 shows the recovery values obtained for AFM 1 580 determination in the certified reference material and in the spiked milk samples 581 by means of ABIA strategy after 4-fold dilution. As can be observed, good 582 recoveries in the ranged of 93-102% were obtained. These values were within 583 the limits established by the EU for analyte concentrations below 1 µg kg -1 (-584 40%/+20%). Taking into account the sample preparation procedure applied, 585
LoD for AFM 1 determination by means of ABIA strategy was experimentally 586 determined as 0.4 ng kg -1 . The repeatability or intra-day precision was 587 evaluated by analyzing five replicates of each sample in the same day. The 588 reproducibility (inter-assay precision) was determined by analyzing five 589 replicated samples, which were spiked with the same amount of AFM 1 , in five 590 consecutive days. The intra-and inter-day precisions were expressed as the 591 percentage relative standard deviation (RSD%). The RSDs were ranged from 592 2-10% and 5-15% for intra-day and inter-day variations respectively, which 593
indicates good precision of the ABIA method.
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As regards the CBIA strategy, the poor recoveries obtained for milk analysis 595 after the extraction pretreatment could be attributed to the influence of matrix 596 components on the biotinylated AFM 1 -BSA-pAb immunocomplex formation and 597 its retention on the microtiter plate. Unlike ABIA method, dilution could not be 598 employed in this case since LoD would compromise AFM 1 analysis according to 599 EU policy. Consequently, dilution was discarded, and an extraction procedure 600 based on the use of immunocolumns was selected. This approach made 601 feasible AFM 1 analysis but at the expense of a precision decrease (Table 3) . 602
The RSD for intra-assay and inter-assay determination of AFM 1 was over 10%. 603
Due to the extraction-preconcentration pretreatment, LoD for CBIA strategy was 604 approximately improved 50-fold (i.e. 0.1 ng kg -1 ) and, consequently, detection 605 capabilities for CBIA strategy were similar to those shown by ABIA method. 606
Finally, both methods were applied to the analysis of commercial products 607 (i.e. raw, pasteurized and ultra-high temperature pasteurized milk) obtained 608 from retail markets and supermarkets. However, as expected, none of them 609 showed detectable levels of AFM 1 . 610 611
Comparison of different methodologies for AFM 1 determination. 612
Analytical figures of merit of ABIA and CBIA procedures were compared 613 with those previously reported in the literature for AFM 1 determination in milk 614 (Table 4) and 0.015 µg mL -1 (Au-80 nm and Ag-80 nm); secondary Ab concentration: 0.5 800 µg mL -1 ; streptavidin-metal nanoparticle conjugates concentration: 0.08 µg mL -1 . 801
Each bar represents the mean ± t·s·n -1/2 for three determinations (P = 95%). 
